• 
• 
• 
• 
• 
• 
• 

• 
• 
• 
• 

• 
• 
• 

• 
• 
• 
• 
• 

Vardenafil for the Treatment of Erectile Dysfunction: A Critical Review of the Literature Based on Personal Clinical Experience

Montorsi F, Salonia A, Briganti A, Barbieri L, Zanni G, Suardi N, Cestari A, Montorsi P, Rigatti P; European Urology 2005 (47)612-621

KEY WORDS: Erectile dysfunction; Vardenafil; Phosphodiesterase type 5 inhibitors; Review

At present, the first-line oral pharmacotherapy for the treatment of the majority of patients with erectile dysfunction (ED) is represented by phosphodiesterase type 5 (PDE-5) inhibitors, of which three are currently available worldwide. Sildenafil, the first PDE-5 inhibitor, was approved in 1998. More recently, tadalafil and vardenafil were introduced to EU and US in 2003/ 2004, respectively.

• This review provides a critical analysis of clinical features of vardenafil emanating from published literature. In addition, the authors included comments and suggestions to readers which derive from their personal experience based on 280 patients treated with vardenafil and which may not necessarily adhere to the product labelling for vardenafil or the other PDE-5 inhibitors. In this regard, 101 published full-length papers were identified through Medline search from January 2000 through May 2004. In additions, 212 abstracts published in peer-reviewed journals from the same period were also considered.
• Extensive experience with vardenafil as reported in peer reviewed literature confirms the important role of vardenafil in the management of patients with ED. The development of each physician's own experience with vardenafil is key to optimise overall satisfaction of this therapy by the patient and his partner.

See the abstract

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15826752&dopt=Citation